Is VYGR a fair buy at 7.97

**Voyager Therapeutics (VYGR) does not appear to be a favorable buy at the current price of $7.97**. Here's why:

1. **Technical Indicators Suggest Caution**:
- The stock is trading near its 5-Day Moving Average ($7.82) and below its 10-Day Moving Average ($7.81) and 20-Day Moving Average ($8.05), indicating a bearish short-term trend.
- The Resistance Level is at $8.1, and the Support Level is at $7.91, suggesting limited upside potential and significant downward pressure.

|Ticker|Name|5-Day Moving Average|20-Day Moving Average|10-Day Moving Average|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|VYGR.O|Voyager Therapeutics|7.8200|8.0473|7.8120|20240710|VYGR|185|

|Ticker|Name|Support Level|Resistance Level|Closing Price|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|VYGR.O|Voyager Therapeutics|7.9100|8.1000|8.08|20240710|VYGR|185|

2. **Overvalued Based on Fundamental Ratios**:
- The Price-to-Earnings (P/E) Ratio is -144.38, which is negative and suggests that the company is not profitable.
- The Price-to-Sales (P/S) Ratio is 5.63, and the Price-to-Book (P/B) Ratio is 1.29, both of which are higher than some industry averages, indicating that the stock may be overvalued.

3. **Analyst Sentiments and Price Targets**:
- The average analyst price target over the next 12 months is $17.00, with a high of $30, which is significantly higher than the current price.
- Given the current price and the analysts' targets, there is a high potential for downside risk if the stock does not experience a significant turnaround.
4. **Market Performance and Insider Activity**:
- The stock has experienced a 1-Year Change of -32.95%, which is a significant decline.
- There have been instances of significant insider selling, which could be a negative signal for investors.
5. **Company Fundamentals and Future Prospects**:
- Voyager Therapeutics is a biotechnology company focused on gene therapy and neurology diseases.
- While the company has potential with its product pipeline, the stock's current valuation does not appear to reflect this potential, given the negative P/E ratio and the recent stock performance.

In conclusion, while VYGR may have long-term potential based on its pipeline and industry focus, the current stock price does not appear to be a fair buy based on the technical indicators, fundamental ratios, and recent performance. Investors should consider these factors and the company's future clinical trial results and regulatory approvals before making an investment decision.